# A case of COVID‐19‐associated C‐ANCA vasculitis, was successfully treated with rituximab therapy

## TL;DR

A patient with a rare immune condition linked to COVID-19 was successfully treated with a combination of steroids and rituximab.

## Contribution

The paper presents a successful treatment case of C-ANCA vasculitis associated with COVID-19 using rituximab.

## Key findings

- The patient was treated with steroids and rituximab for C-ANCA vasculitis linked to COVID-19.
- The treatment was effective without significant adverse reactions.
- This case adds to the limited evidence on managing this rare condition.

## Abstract

Both C‐anti‐neutrophil cytoplasmic antibody (ANCA) and P‐ANCA vasculitis were reported to be associated with COVID‐19 infection. The ideal management of COVID‐19‐associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID‐19‐associated C‐ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.